News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–41
Matches
41
Sources here
5
Companies here
1
Search results Stored financial headlines

Active search

41 matching headlines

Ticker or company: VRDNMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

Viridian Therapeutics (VRDN) Stock Analysis: A Biotech Gem with Nearly 95% Upside Potential

Viridian Therapeutics (VRDN) is identified as a promising biotechnology company with significant growth potential, particularly in developing treatments for thyroid eye disease (TED) and Graves’ disease. Despite typical biotech financial metrics showing early-stage development, analysts forecast a nearly 95% upside potential, with an average …

VRDN main company
Sharemaestro market context Price above Trend Line 52 weeks +14.9% VRDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Analyst action Main company 🇺🇸 United States

Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31

Wells Fargo has reiterated its Buy rating for Viridian Therapeutics (VRDN.US) and maintained its target price at $31. This indicates a continued positive outlook from the firm regarding the company's stock performance.

VRDN main company
Sharemaestro market context Price above Trend Line 52 weeks +14.9% VRDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Viridian Therapeutics (VRDN) Goldman Sachs 46th Annual Global Healthcare Conference summary

Viridian Therapeutics showcased its progress at the Goldman Sachs 46th Annual Global Healthcare Conference, highlighting positive Phase 3 data for its active and chronic Thyroid Eye Disease (TED) treatments, with BLA filing targeted for the second half of the year. The company emphasized the …

VRDN main company
Sharemaestro market context Price above Trend Line 52 weeks +14.9% VRDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Market update Main company 🇺🇸 United States

Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today

Viridian Therapeutics (VRDN) stock has dropped 37.8% year-to-date, but despite this decline, valuation checks suggest it remains expensive, trading at a high P/S ratio of 29.7x compared to industry averages. The tailored Fair Ratio further indicates overvaluation, although this can also serve as a …

VRDN main company
Sharemaestro market context Price above Trend Line 52 weeks +14.9% VRDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

VRDN6389238 Bond Coupon Profile — Rate & Payments

This article provides key details about the Viridian Therapeutics, Inc. VRDN6389238 bond. It highlights the current coupon rate of 1.75% and indicates that the next interest payment is scheduled for November 16, 2026. The piece also notes that further in-depth coupon data and an …

VRDN main company
Sharemaestro market context Price above Trend Line 52 weeks +14.9% VRDN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context